Translational Medicine

An increasingly important biomedical speciality

Webinars, events, articles and multi-media lectures

Back

Dr. Aoife Brennan

President & CEO

Synlogic

Dr. Aoife Brennan is an experienced physician scientist and drug developer responsible for the successful clinical development and registration of multiple transformative medicines. Aoife has served as Synlogic’s president and chief executive officer since May 2018.

Aoife joined Synlogic in September 2016 as chief medical officer. Prior to Synlogic, Aoife spent six years at Biogen, most recently as vice president and head of the Rare Disease Innovation Unit, developing programs from pre-clinical to commercial. She has led programs across multiple therapeutic areas including the successful late phase development & registration of SPINRAZA® (nusinersen) for spinal muscular atrophy and ALPROLIX® and ELOCTATE® for Hemophilia B and Hemophilia A, respectively.

Aoife serves as a member of the Board of Directors of Cerevance and Fibrogen, Inc, and previously served on the Board of Directors of Ra Pharmaceuticals until its acquisition by UCB. Earlier in her career, Aoife led clinical development at Tolerx, a start-up biotech company focusing on immunotherapy for Type 1 diabetes.

Webinars, events, articles and multi-media lectures

Sign up to hear from us:

CONTACT US
Ruskin House, 40-41 Museum Street, London WC1A 1LT, UK

Henry Stewart Conference Studies LLP is a limited liability partnership, registered in England, registration number OC334769 with its registered office at 40-41 Museum Street, London WC1A 1LT. Henry Stewart Events Ltd is a limited company, registered in England, registration number 06532399 with its registered office at 40-41 Museum Street, London WC1A 1LT. Henry Stewart Events, Inc. is a corporation incorporated in the State of Delaware, USA having a business office at PKF O’Connor Davies LLP, 665 Fifth Avenue, New York NY 10022.
© Henry Stewart Conference Studies LLP or its affiliates.